跳至主要内容
临床试验/JPRN-UMIN000005639
JPRN-UMIN000005639已完成未知

Efficacy of dose modification based on therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections associated with hematological diseases - Efficacy of dose modification based on therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections associated with hematological diseases

Department of Hematology and Oncology, University of Tokyo Hospital0 个研究点目标入组 50 人开始时间: 2011年6月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • a. QT elongation (QTc > 0.46 ms) by EKG b. Patients who are susceptible to fatal arrythmias such as ventricular tachycardia c. Use of contraindicated drugs at enrollment: rifampicin, rifabutin, efavirenz, rithnavir, carbamazepine, barbital, phenobarbital, pymozide, quinidine, ergotamine(alkaloids), triazolam, bepridil, simvastatin, azelnidipine, nisoldipine, vardenafil, eplerenone, blonanserin, sildenafil, tadalafil. d. Concomitant use of other antifungal agents unless they can be stopped at the time of enrollment

研究者

发起方
Department of Hematology and Oncology, University of Tokyo Hospital

相似试验